A concerning resurgence of diphtheria, a potentially fatal bacterial infection, is unfolding in South Africa, with the National Institute for Communicable Diseases (NICD) reporting two additional laboratory-confirmed cases in the Western Cape. This brings the total to 12 confirmed respiratory cases and two asymptomatic carriers identified since late December 2025 – all concentrated within the Western Cape province. While diphtheria was largely considered a disease of the past due to widespread vaccination, this outbreak signals a critical vulnerability in population immunity and a potential warning for other regions.
- Resurgence of a Preventable Disease: South Africa is experiencing a localized outbreak of diphtheria, a disease dramatically reduced by vaccination programs globally.
- Geographic Concentration: All identified cases and carriers are currently limited to the Western Cape, suggesting localized factors impacting vaccination rates or access to healthcare.
- Early Treatment is Critical: The NICD emphasizes the need for immediate treatment – including antibiotics and diphtheria antitoxin – *before* laboratory confirmation, highlighting the disease’s rapid progression and potential for severe complications.
Diphtheria is caused by Corynebacterium diphtheriae bacteria, and infection occurs through close contact with an infected individual or respiratory droplets. The disease produces a toxin that can damage the heart, kidneys, and nervous system. The median age of those affected in this outbreak is 28, with a significant proportion being adults, and tragically, one fatality occurred in a child under the age of 10. This age distribution underscores the importance of booster vaccinations, as immunity wanes over time, and highlights potential gaps in childhood vaccination coverage.
The case-fatality rate of 8% in this outbreak, while relatively low, is a stark reminder of the disease’s severity. The clinical presentation – sore throat, fever, and the characteristic thick grey membrane in the throat – is crucial for early diagnosis. However, the NICD stresses that treatment should not be delayed pending laboratory confirmation, given the potential for rapid deterioration and the life-saving impact of diphtheria antitoxin.
The Forward Look
This outbreak is not simply a localized event; it’s a canary in the coal mine. Several factors likely contribute to this resurgence. Declining vaccination rates globally, fueled by vaccine hesitancy and disruptions to healthcare systems (including those experienced during the COVID-19 pandemic), are creating pockets of susceptibility. Furthermore, increased international travel could introduce the bacteria into new areas.
What to watch for: We can anticipate increased surveillance efforts in the Western Cape and potentially other provinces. Public health officials will likely launch targeted vaccination campaigns, particularly focusing on at-risk populations and booster doses for adults. The NICD’s data will be closely monitored to determine if the outbreak is contained or if it expands geographically. Crucially, this situation will likely prompt a broader review of vaccination coverage rates and strategies across South Africa, and potentially serve as a wake-up call for other nations facing similar challenges in maintaining high immunization levels. The success of this response will hinge on rapid diagnosis, aggressive treatment, and a renewed commitment to preventative healthcare measures.
Discover more from Archyworldys
Subscribe to get the latest posts sent to your email.
